Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
50%
Ph not_applicable
1
25%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Other(1)

Detailed Status

Active, not recruiting1
Completed1
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (66.7%)
N/A1 (33.3%)

Trials by Status

active_not_recruiting125%
completed125%
recruiting125%
unknown125%

Recent Activity

2 active trials
Showing 4 of 4
active_not_recruitingphase_2

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

NCT04904588
completed

Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database

NCT01937052
recruitingphase_2

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

NCT06019130
unknownnot_applicable

QSPainRelief-patientCNS : Clinical Biomarkers of Nociception, Sedation and Cognition

NCT04742790

Clinical Trials (4)

Showing 4 of 4 trials
NCT04904588Phase 2

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Active Not Recruiting
NCT01937052

Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database

Completed
NCT06019130Phase 2

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

Recruiting
NCT04742790Not Applicable

QSPainRelief-patientCNS : Clinical Biomarkers of Nociception, Sedation and Cognition

Unknown

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4